Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 43.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 408,043 shares of the company’s stock after buying an additional 124,558 shares during the quarter. Sei Investments Co.’s holdings in Cellebrite DI were worth $8,989,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in CLBT. True Wind Capital Management L.P. grew its stake in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the last quarter. FMR LLC lifted its holdings in shares of Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after purchasing an additional 3,239,307 shares during the period. Pembroke Management LTD grew its position in Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock valued at $43,893,000 after buying an additional 84,087 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Cellebrite DI in the 3rd quarter valued at $23,402,000. Finally, Two Sigma Advisers LP raised its position in Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after buying an additional 120,000 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Down 0.8 %

Shares of NASDAQ CLBT opened at $19.46 on Monday. The firm has a 50-day moving average price of $20.85 and a 200 day moving average price of $19.91. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The stock has a market capitalization of $4.66 billion, a price-to-earnings ratio of -14.00, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

CLBT has been the topic of several analyst reports. Lake Street Capital lifted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Thursday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.